The NAD+ precursor has therapeutic potential against Parkinson’s disease
We will look at a study that shows that a NAD+ precursor can improve mitochondrial function both in flies and cells with a Parkinson’s model.
You can read more about it here:
Although mitochondrial dysfunction has been implicated in Parkinson’s Disease (PD), the question still remains as to whether or not mitochondria are actually disease drivers, and whether boosting biogenesis and mitochondrial function can ameliorate pathology. These questions are addressed using Drosophila and patient-derived induced stem cells. GBA-related PD is the most common genetic risk for PD. Stress responses are evident in patient neurons, as well as mitochondrial death and changes to NAD+ metabolism. NAD+ precursors are proposed as a way to combat age-related metabolic decline. The NAD+ precursor nicotinamide riboside NR significantly improves mitochondrial function of patient neurons. Human neurons require nicotinamide phosphoribosyltransferase (NAMPT) to maintain the NAD+ pool and utilize NRK1 to synthesize NAD+ from NAD+ precursors. NR is able to prevent the age-related loss of dopaminergic neurons and motor decline seen in fly models with GBA-PD.
Source:
https://www.leafscience.org/nicotinamide-riboside-has-therapeutic-potential-against-parkinsons-disease/
